Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can shingrix shield HIV patients from shingles?

NCT ID NCT05580458

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 4 times

Summary

This study tests the Shingrix vaccine in people with HIV and healthy volunteers to see how well it boosts immunity against shingles. Participants receive two shots two months apart and are followed for a year. The goal is to understand if the vaccine works safely in those with different CD4 counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Shingrix vaccine
What this could lead to
If successful, this study could show that Shingrix works well in people with HIV, helping protect them from shingles.
What could go wrong
This is an early-phase trial with only 225 participants, so results may not apply to everyone. The vaccine may cause side effects like pain or fever.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HERPES ZOSTER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.